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Abstract 
Presumptive drug testing is commonly used in both the clinical and forensic fields to 
allow rapid identification of the presence and/or usage of drugs. Because the tests 
generally have a high sensitivity and specificity (often >90%), then a positive test result 
may be taken to mean there is a high probability that a targeted drug is present.  This 
assumption is, however, incorrect. This paper demonstrates how, in order to assess 
the positive predictive value (PPV) of a test, it is necessary to take into account, along 
with the sensitivity and specificity of the test, the prevalence of the drug in the 
population being investigated.  We demonstrate how an alternative, Bayesian 
approach to assessing the posterior probability of a drug being present mimics the 
conventional calculation of PPVs but, because a Bayesian approach requires case-
specific prior probabilities, the posterior probabilities are more meaningful than PPV in 
any one specific case.  The effectiveness of presumptive test results in cases such as 
drink-spiking, drug-driving, testing of drugs during seizures and the confirmation of 
initial presumptive test results is explored.  
In order to exploit the potential of presumptive drug testing, it is important that the 
prevalence of the targeted drugs in relevant populations is understood but, more 
importantly, it is important to consider using a Bayesian approach in order to tailor 




Presumptive/screening tests are used to provide information to facilitate decisions 
about any further analyses that may be required. These preliminary tests are usually 
carried out as they are quicker and cheaper than more advanced laboratory tests or 
because the testing needs to be carried out in locations (such as a crime scene or at 
the bedside) which are usually not as easily accessible to more advanced (and usually 
less portable) analytical equipment. Presumptive screening tests are usually either a) 
a simple chemical reaction, where the targeted substance reacts with a chemical to 
give a certain colour (Harper, Powell, & Pijl, 2017) or b) an immunoassay, where an 
antibody specific to the substance or chemical group/ moiety binds to give a colour 
result on binding (Harper et al., 2017). More recently, Raman spectroscopy and 
electrochemical sensors have been developed for presumptive drug testing that allow 
the determination of the presence of a wider range of drugs but are more expensive 
than colour and immunoassay testing (Florea, de Jong, & De Wael, 2018; West & 
Went, 2011).  The ideal aim in drug screening would be to identify correctly all of the 
cases in which the substance being targeted is present and not incorrectly give a result 
when the targeted substance is not present.  There are four possible outcomes to a 
screening test: 1) a true positive (TP) where an individual has taken the targeted drug 
and the test indicates a positive; 2) a true negative (TN) where an individual has not 
taken the targeted drug and the test give a negative result; 3) a false positive (FP) 
where an individual has not taken the targeted drug but the test returns a positive 
result; 4) a false negative (FN) where an individual has taken the targeted drug but the 
test gives a negative result.  
The conventional approach in toxicology to assess the performance of a test has been 
to calculate two metrics: -  
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a) Sensitivity - the proportion of individuals who were correctly identified by the 
screening test as having taken the drug (true positives only) among all individuals who 
have taken the drug (true positives and false negatives)  
Sensitivity = TP/(TP+FN)         (1) 
b) Specificity - the proportion of individuals who were correctly identified by the 
screening test as not having taken the drug (true negatives only) among all those who 
have not taken the drug (true negatives and false positives) 
Specificity = TN/(TN+FP)          (2) 
Modern drug screening methods generally have sensitivities and specificities above 
90 – 95%.  Intuitively, given these figures, a user of these tests might well assume 
that, for any one given individual with a positive result, it was ~90 – 95% certain the 
individual had consumed the drug and only ~5 – 10% probability that they had not. 
However, in practice this is not true – a frequently overlooked but important factor 
affecting the prior probability that an individual has (or has not) taken a drug is the 
prevalence of use of that drug in the population of which the tested individual is a 
member. 
 
How prevalence is important in determining the effectiveness of a screening test 
Let us assume that we have a screening test (Test A) that has a 98.7 % true-positive 
rate (sensitivity) and a 2.5 % false-positive rate (97.5 % specificity).   We wish to 
assess the effectiveness of this test in assessing if an individual has consumed a drug. 
For this example, we focus on cocaine use among drivers. The European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) compiled epidemiological data on the 
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prevalence of drug abuse in drivers in Europe (EMCDDA, 2014).  From this study, is 
it possible to estimate the mean prevalence of cocaine in the general driving 
population as 0.42 %. This statistic, along with the metrics of sensitivity and specificity, 
allow us to determine the false discovery rate (FDR) (Colquhoun, 2014), i.e. the rate 
at which, if people test positive, they have not actually consumed the drug, and its 
complement, the positive predictive value (PPV), i.e. the rate at which, if people test 
positive, they have actually consumed the drug.  A simple way to illustrate these two 
characteristics of the test is through the use of a tree diagram, as shown in Figure 1.  
It shows that, if a driver is taken at random from the European population and tests 
positive using this screening test, they have only a 14% probability (positive predictive 
value (PPV)) of actually having consumed cocaine, very different from the intuitive 
assumption that, given a person had tested positive, then there would be a high 
probability (~90 – 95%) that that person had consumed cocaine.  
   
Bayes Theorem as an alternative model to assess the effectiveness of a 
presumptive test 
Bayes Theorem has been proposed extensively in forensic science and other domains 
as a logical means of dealing with uncertainty  (such as (Institutes, 2015; Linnet, 
Bossuyt, Moons, & Reitsma, 2012; Robertson, Vignaux, & Berger, 2016)).  Bayes 
Theorem shows how the posterior probability (the probability after the test result is 
known) of the drug being present in the individual’s sample depends not just on the 
metrics of sensitivity and specificity for the test but also on the prior probability of the 
drug being present in that individual. 
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A common depiction of Bayes Theorem in forensic settings is in terms of odds 
(mathematically related to probability, see equations 3 and 4).   
 
𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂 =  𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃
1−𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃
          (3) 
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 =  𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂
1+𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂
         (4) 
In the case of cocaine consumption, the Theorem may be written as:  
Odds[C|Tpos] = Odds[C] x LR[Tpos]                   (5) 
where Odds[C|Tpos] is the posterior odds of cocaine being present, given a positive 
test result; Odds[C] is the prior odds of cocaine being present; and LR[Tpos] is the 
likelihood ratio (LR) provided by the positive test result. The prior odds of cocaine 
being present in the individual’s sample (Odds[C]) should be assigned on the basis of 
what is known about that person but, in the absence of any specific information on that 
person that would influence these odds, a pragmatic estimate could be obtained from 
the prevalence of cocaine use in the general population of the country in question.  
However, it should be stressed that a probability based on general prevalence may 
misleadingly inflate or deflate the prior probability against or in favour of the individual.  
From the published data (EMCDDA, 2014), a prior probability that cocaine would be 
present in a sample from someone chosen at random in Europe could be assigned a 
value of 0.42%.  The prior odds of C (Odds[C]) would then simply be the ratio of this 
probability to its complement, i.e. 0.0042/0.9958, or 0.00422.   
The likelihood ratio for a positive test result (LR[Tpos]) is the ratio of the probability of 
observing that test result given that cocaine was present to the probability of the test 
 7 
result given that cocaine was not present.   These two probabilities can be assigned 
essentially from the sensitivity and specificity metrics, i.e. 0.987 and 0.025.  Tables 1 
-3 show how the metrics for sensitivity and specificity map across to the calculation of 
an LR.  The LR for a positive test result is given by dividing the two values of probability 
in the horizontal line for a positive test result (these two values represent, respectively, 
specificity and 1 - sensitivity).  The LR is then 0.987/0.025, or 39.48. 
The posterior odds of a person having consumed cocaine given a positive test result 
(Odds[C|Tpos]) is then the product of the prior odds and the LR, i.e 0.00422 x 39.48.  
This gives a value of 0.166 for the posterior odds.  
The posterior odds can be converted to posterior probability using equation 3.  
Converting odds of 0.166 back to probability gives a posterior probability of cocaine 
being present as  0.166
1+0.166
   or 0.142 (14.2 %). This means that, even given a positive 
test result, it is unlikely that cocaine is actually present.  Note that this probability has 
the same value the positive predictive value as given by the conventional calculation 
using prevalence, sensitivity and specificity detailed earlier. 
The LR values shown in Table 3 include not only the LR that is provided by a positive 
test result (39.48) but also that provided by a negative test result (0.13).  While 
obtaining a negative test result will very likely mean no further action will be taken, it 
is interesting to see the impact of such a result on the odds of cocaine being present.  
If we start with the same prior odds of cocaine being present as before (0.00422), then 
an LR of 0.13 provided by the negative test will give posterior odds of 0.00055 for 
cocaine being present.  This equates to a posterior probability of 0.00055 (rounded) 
or 0.055%.   
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The interplay of prevalence and predictive value 
Returning to the conventional calculation for the moment, it is possible to demonstrate 
how prevalence influences the positive predictive value of the cocaine test. Figure 2 
illustrates how the positive and negative predictive values for the cocaine test 
(sensitivity 0.987; specificity 0.975) are altered by the prevalence of the number of 
people consuming cocaine. These data show that to have PPV of 90% (individuals 
being correctly identified as having consumed cocaine given a positive test result) will 
require a prevalence in the population being sampled of ~20% and that the prevalence 
in the population will need to be 50% for the PPV to equal the sensitivity and specificity 
of the test.  
These two figures for prevalence can again be confirmed using Bayes Theorem.  A 
prevalence of 20% is equivalent to a prior probability of 0.20 (i.e. prior odds of ¼ from 
equation 4:  0.20
1−0.20
 = 0.25).  If these prior odds of 0.25 are multiplied by the LR (for the 
positive test result) of 39.48, the resulting posterior odds are 9.87, giving a posterior 
probability of 0.91.  A prevalence of 50% is equivalent to a prior probability of 0.5 (i.e. 
prior odds of 1).  When multiplied by an LR of 39.48, the posterior odds are 39.48 and 
the posterior probability 0.975.  These two values for the posterior probability are the 
same as the PPV values calculated earlier using prevalence, sensitivity and specificity.   
Using an appropriate prevalence in the population is important to assess the positive 
predictive value of a test. In the above example, we assumed the individuals being 
tested were being selected at random. In most legal jurisdictions however, law 
enforcement will not randomly stop drivers. They will stop individuals on the basis that 
they believe them to be driving under the influence of drugs (DUID) and this is likely 
to increase the positive predictive value of the screening tests because the prevalence 
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in such a group may well be greater than in the general population. This theory is 
backed up from field studies in which drivers suspected of DUID (cocaine) by law 
enforcement exhibited a prevalence of cocaine use of between 2 and 14%  (Gjerde, 
Clausen, Andreassen, & Furuhaugen, 2018; Lema-Atán, de Castro, Lendoiro, López-
Rivadulla, & Cruz, 2019; Musshoff, Hokamp, Bott, & Madea, 2014; Strano-Rossi et al., 
2012; Tang et al., 2018). These suspected DUID drivers showed a prevalence of 
cocaine use around 4 to 28 times higher than the general population. These data 
demonstrate that studies should be carried out to assess the prevalence of drug usage 
in the targeted population in order to give a better-informed view of the positive 
predictive value of any test.   
In Bayesian terms, the probability that the individual being tested had, a priori, 
consumed cocaine should be assigned according to what is known about that 
individual.  That information may increase or decrease the value indicated by 
prevalence studies. A benefit of Bayes Theorem is in this individual approach to 
assigning priors that, in turn, result in case-specific, posterior probabilities. 
 
Prior probability and confirmatory testing 
It is accepted in the forensic and clinical fields that all presumptive screening tests 
should be confirmed with a secondary test based on a different chemical principal to 
increase the confidence that the initial result was not a false positive (Elliott, Stephen, 
& Paterson, 2018). This is particularly important in the forensic field where an incorrect 
positive testing result could lead to an individual losing their job, losing custody of their 
child or being incarcerated. Although it is generally assumed that a so-called 
confirmatory test would give absolute certainty that a positive presumptive test result 
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actually means the drug is present, this is not always the case - the degree of certainty 
(or positive predictive value) of the two tests would again depend on the prevalence 
and the performance characteristics, in terms of sensitivity and specificity, of the two 
tests.  However, because there will always be some level of correlation between the 
two tests, likely to be low due to the use of tests with different chemical principal, the 
PPV of the combination of the two tests will most likely be an overestimation. Ideally, 
the combined PPV of the two testing methods would be determined by running a study 
with the tests in series and combining the overall results.  
The overall PPV of combined tests could be illustrated using the conventional 
terminology and calculations that we presented earlier.  However, we believe that the 
alternative approach of conditional probabilities within Bayes Theorem provides a 
more tractable and transparent means of illustration.  
Let us assume that the presumptive test to be used is the one described earlier – we 
will call this Test A.  The probabilities of the observations (the positive and negative 
test results), and LRs provided by these observations, for Test A are shown in Table 
3.  Remember that the probabilities reflect the rates of sensitivity and specificity of 
98.7% and 97.5% respectively.  However, unlike our earlier example, a prior 
probability of 0.5 (50%) for the drug being present in the tested individual will be used 
instead of a probability of 0.0042 (0.42%) that was based on prevalence studies.   








Posterior odds of 39.48 equates to a posterior probability of 0.975 (97.5%) for the drug 
being present.  So, the impact of the positive test result has been to change the 
probability of drug being present from 0.5 (50%) to 0.975 (97.5%). 
Assume now that we wish to use a so-called confirmatory test, Test B.  Also assume 
that, in trials of Test B, not associated with Test A, Test B has been assessed as 
having a sensitivity of 99.0 % and a specificity of 99.0 %.  The probabilities for the test 
observations, and the LRs derived from them, based on these metrics are shown in 
Table 4.  It might be tempting, if a positive result is obtained with Test B, to follow the 
same steps as for Test A and multiply prior odds of 0.5/0.5 (a prior probability of 0.5) 
by the LR value of 99 (Table 4) for a positive observation to give posterior odds of 99 
(equivalent to posterior probability of approx. 0.99 (99%)) for the drug being present.  
However, this would be wrong on two counts.  Firstly, the prior odds for Test B are not 
0.5/0.5 because the outcome of Test A has changed those odds to 39.48 (probability 
97.5%).  Therefore, the prior odds for Test B should be 39.48.  Secondly, the metrics 
of sensitivity and specificity for Test B were assessed independently from any results 
obtained using Test A, i.e. they were not conditioned on the outcome of Test A.  
Therefore, the probabilities assigned from these metrics will not take into account any 
dependency between the tests.  To assess logically and safely the combined effect of 
Test A and Test B results, we need to ensure that any dependency between them has 
been accommodated.  Ideally, we need data from studies of the performance of Test 
B on samples that were positive in Test A.  Table 5 illustrates probabilities based on 
such data which, in this instance, are hypothetical.  Note the apparent sensitivity and 
specificity are now 99.9% and 90% instead of 99% and 99% as in Table 4. Note also 
the impact on the magnitude of the LRs – for a positive test result, the LR has been 
reduced from 99 to approximately 10, an order of magnitude lower.  In actual practice, 
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tests A and B will be chosen on the basis that they identify the analyte concerned using 
different chemical principals and, therefore, the assumption is that the results are not 
correlated.  Our example shows there is a degree of correlation between the two tests 
that may overestimate that which occurs in practice but we stress the only way to 
assess the degree of correlation, even when using orthogonal tests, is to conduct 
controlled experiments to acquire the relevant data to justify the metrics used when 
evaluating the results of a combination of tests.  
We can now calculate revised posterior odds for the combination of positive results in 
both tests.  In this new calculation, the posterior odds resulting from a positive test A 
become the new prior odds for the result of Test B.  These odds are multiplied by the 





=  394 
Posterior odds of 394 equate to a posterior probability of 0.997 (99.7%).  So, the 
outcome of Test B has changed the posterior odds by about an order of magnitude 
from 39.48 to 394. 
Had we used the unconditional LR of 99 for the positive Test B, the posterior odds 
would have resulted in a misleading hundred-fold increase in the posterior odds from 
39.48 to 3,908. 
Table 6 illustrates the impact of different values for the prior probability of the drug 
being present in an individual for Test A in isolation and for the combination of Tests 
A and B.  At a low value of prior probability of 1 %, a secondary confirmatory test will 
only give 29% certainty of the drug being present, given positive results in both tests. 
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Increasing values of prior probability will, of course, increase the posterior probability 
but it is only when the prior probability is greater than 2% does the posterior probability 
exceed 90% for the combination of both tests.  A prior probability of 50% will result in 
a posterior probability of 99.8% - presumably a value that would satisfy the decision-
maker that the drug was indeed present.  The overall posterior probability would of 
course vary with the sensitivity and specificity of the testing methods being used at 
each stage, but it is important for forensic and clinical practitioners to understand that 
a confirmatory test may not be as good as it appears, particularly if the prior probability 
of the drug being present in the individual being tested is low.   It is also vital that any 
conditionality between the outcomes of separate tests run in series is accommodated 
in the evaluation of the results. 
 
Further comments on low priors - screening of drinks for potential “spiking”  
In forensic toxicology, there is a lack of knowledge of the prevalence of drugs in certain 
groups or populations.  As we have shown, this knowledge is essential to inform the 
assigning of realistic, justifiable, prior probabilities which, in turn, facilitate a better 
understanding of the relevance of test results.  One such area of limited knowledge of 
prevalence is that of alleged spiking of drinks.  Because of the clandestine nature of 
drug-facilitated sexual assault (DFSA), it is very difficult to determine the incidence of 
not only drug-facilitated DFSA in individual countries but also of the drugs that have 
been utilised.  Some information on the frequency of use of specific drugs in alleged 
cases of DFSA is provided by a US study (March 2015- June 2016) of 1000 cases of 
suspected DFSA (Fiorentin & Logan, 2019).  The authors provide data on the 
frequency of detection of a very wide range of drugs in blood and/or urine samples 
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from DFSA complainants.  We will select just three drugs from this study - γ-
hydroxybutyrate (GHB), ketamine and diazepam – to illustrate the principles of the 
assessment of posterior probabilities of a drink having been spiked.  The frequencies 
of detection of these three drugs are quoted as 5.9%, 0.5%, and 3.7% respectively 
and are summarised, along with the frequencies of some other DFSA drugs, in Table 
7.  An earlier study in the UK of 1014 cases of alleged DFSA (Scott-Ham & Burton, 
2005), again based on analysis of complainants’ blood/urine samples, found that a 
sedative or disinhibiting drug was detected in 18% of cases but, of these, only 2% 
were considered, based on other evidence, as involuntary ingestion.  There is no 
breakdown for individual drugs in this category.  
For any Bayesian analysis, it is vital that the issue being investigated is clearly 
identified and specified from the outset.  Clarity about the issue leads to clarity about 
the specific hypotheses (and their negations) that are being evaluated.  In drink-spiking 
cases, one issue is that of whether the complainant had consumed a DFSA drug.  
However, because we are dealing here with presumptive tests for “drink-spiking”, the 
issue has to be one of whether a drink had been “spiked”. The issue of whether a 
complainant had consumed a DFSA drug would be best addressed through analysis 
of body fluid or tissue samples from the complainant.  Given that the issue to be 
addressed here is that of whether the drink had been “spiked”, then the specific 
hypothesis would be “The drink had been spiked” and its negation “The drink had not 
been spiked”.  The question now is how to assign a prior probability for that hypothesis.  
Information from studies on the incidence of DFSA drugs in complainants’ blood/urine 
samples could be helpful but that information is at least one step removed from the 
central issue of whether the drink was spiked.  There is very little, if any, information 
on the occurrence of DFSA drugs actually in the drinks of complainants to help inform 
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prior probabilities.  If absolutely no information were available, then a prior of 50% 
would be appropriate to reflect maximum uncertainty about whether the drink had been 
spiked.  However, given that there is some information to help, we could assign priors 
based on data from the US and/or UK studies, according to jurisdiction.  However, 
only the US study breaks down prevalence according to drug type and, accordingly, 
we will base our prior probabilities on these data.  For comparative purposes, we will 
also use a 50% prior for each drug to illustrate the effect of assuming maximum 
uncertainty.  Values of prior probability are, of course, open to adjustments to reflect 
the specific conditions of the case. 
Having assigned prior probabilities, we now need to assign conditional probabilities of 
observing positive and negative outcomes of the tests given a drink had or had not 
been spiked.  Information to inform these probabilities can be obtained from 
independent studies, such as using the sensitivity and specificity of three presumptive  
“drink spiking” tests - Drinksafe 1.2; Drink Guard and Drink Detective  (Beynon, 
Sumnall, McVeigh, Cole, & Bellis, 2006; Quest & Horsley, 2007).  Table 8 shows the 
sensitivity and specificity data from these sources based on independent testing.  
Table 9 shows the probabilities assigned from these data and the LRs that result from 
the probabilities.  Overall, the values of LRs for positive observations are not 
particularly high.  The impact of such LRs on the prior probabilities will therefore not 
be great.  The largest LR, of value 8.26, is that for Drink Detective test for ketamine, 
while the lowest LR is of value approximately 1 for Drink Guard’s test for Ketamine.  
An LR value of 1 means the test result does not help at all in updating the prior 
probability – basically, the positive test result is uninformative.  With regard to negative 
test results, with one exception, the values of LR range from approximately 1 to 0.21 
(1/5).  An LR value of one, as just explained, provides no help in updating uncertainty 
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while an LR of 1/5 (0.21) means that the prior odds (the ratio of the prior probability to 
its complement) of the drug being present will be multiplied by a factor of 1/5 given a 
negative test result.  The exception for negative results is that for Drink Detective’s 
test for Ketamine, where the LR is of value zero.  This value has resulted from the zero 
value that has been assigned to the probability of obtaining a negative test result if the 
drug is indeed present.  In probabilistic reasoning, a value of zero for an event means 
that that event is impossible to observe given the condition.  However, it is unjustifiable 
to assert a probability of zero from observations taken from a limited sample, 
especially with a sample size of only 20.  It might be that, if a sufficiently large sample 
were to be studied, that event will be observed.  It is more justified, therefore, to assign 
a small probability for that event.  For the purposes of this paper, however, we will 
proceed on the basis that the value of zero can be justified. 
Equation 5 can now be used to give the posterior probability of a drink having been 
spiked with each of the three drugs, given positive test observations and given two 
values of prior odds.  Table 10 shows the posterior probabilities given prior 
probabilities that reflect prevalence of the drugs as shown in Table 7 while Table 11 
uses a prior probability that reflects maximum uncertainty.  
The posterior probabilities shown in Table 10 range from 0.40 (40%) down to 0.005 
(0.5%).  So, even with the best performing test in terms of the magnitude of the LR, 
i.e. Drink Detective’s test for ketamine (LR=8.26), the posterior probability of the drug 
being present is only approximately 4%.  Drink Safe 1.2’s test for GHB (LR=5.95) gives 
a higher posterior probability of 27% but that is because the prior probability is that 
much higher for GHB (5.9%) than for diazepam (3.7%).  A positive result for Ketamine 
using the Drink Guard test does not change the prior probability at all because the LR 
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of value 1 is uninformative – the probability of the drug being present (0.5%) is 
unchanged by the positive test result.   
In general, even if the user of a “drink spiking” presumptive test gets a positive result 
then, for all of the drug/test kit combinations shown in Table 10, it is unlikely (in some 
cases, very unlikely) that the drug is truly present in the drink.  It must be stressed that 
these values for posterior probabilities for the drug being present in the drink are 
predicated not just on the reliability of the performance metrics of sensitivity and 
specificity but also on the appropriateness of the assigned prior probabilities.  If we 
increase the priors to reflect maximum uncertainty, then the effect on posterior 
probability can be seen in Table 11.  A positive result using the best performing test 
(in terms of LR magnitude) the Drink Detective diazepam test now provides a posterior 
probability of 89% for the drug being present in the drink.  A weaker-performing test, 
such as Drink Detective’s test for GHB, now provides a posterior probability of 59% 
for the drug being present.  As explained earlier, test results that provide LRs of value 
1 are uninformative and therefore do not change the prior probabilities at all.   
Aside from apparently ineffective tests, i.e. those providing LRs of 1, the presumptive 
tests examined in this paper do not provide what may be described as very high 
posterior probabilities of a drink being spiked unless the prior probability is also 
relatively high. 
However, while the posterior probabilities may not be high, the best advice in the 
interest of safety, given the prevalence figures from the literature, would still seem to 
be to discard drinks that give positive test results.  
Turning now to the meaning of negative test result, we show in Tables 12 and 13 the 
posterior probability of a drug being present given that a negative result has been 
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observed and given two different prior probabilities (as in Tables 10 and 11).  With the 
exception of results that give LRs of value 1 or zero, all posterior probabilities are lower 
than the prior probabilities when a negative result is obtained.  Table 12 shows that, if 
prior probabilities based on prevalence are used, the posterior probabilities of drug 
being present are very low, ranging from 5.9% down to 0.26%.  For those results that 
have LR values of 1, the prior probability remains unaltered.  For the test result that 
has an LR of value zero, Drink Detective’s Ketamine test, a negative result gives a 
posterior probability of value zero, meaning the drug is certainly not present in the 
drink.  But, as we have mentioned, this inference is predicated on a probability, and 
hence an LR, of zero being justified. 
Table 13 is equivalent to Table 12 but with a prior probability that reflects maximum 
uncertainty.   As would be expected, the posterior probabilities of a drug being present, 
given a negative result, are lower than their prior probabilities, with the exception of 
those tests that have an uninformative LR of 1.   Posterior probabilities range from 
17% to 39% for those tests that have an informative LR.  Those values may not be 
reassuring to someone using those tests to check whether a drink is clear of a DFSA 
drug.   
Overall, a decision on whether a drink has been spiked depends critically on two 
factors – 1) the reliability of the performance metrics of the test and 2) the prior 
probability of the drink having been spiked.  The reliability of the performance metrics 
will depend on how closely the conditions of the performance study reflects real-life 
situations and on the size of the sample.  The reliability of prior probabilities will depend 
on how closely those probabilities reflect the individual’s circumstances.  For example, 
if the drink being tested was that of a young male in a nightclub in Dundee, Scotland, 
it would be preferable to base the prior probability on data about the prevalence and 
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identity of drugs used for surreptitious drugging in the drinks of males between the 
ages of, say, 18 – 25 in nightclubs in Dundee.  Often though, data of this kind, tailored 
to the specific case in hand, is just not available.  A pragmatic approach would be to 
take whatever data there may be on prevalence and adjust those data for what is 
known about the circumstances of the case in hand.  The sensitivity of the choice of 
priors can be assessed by exploring alternative values for those priors but, in the 
absolute absence of any expert insight into what may be an appropriate value for the 
prior, a value of 0.5 for the prior probability, reflecting maximum uncertainty, could be 
adopted.   
 
Comment on large priors - drug seizures and cost-benefit analysis. 
Presumptive testing is often used on a questioned powder or tablet when an initial 
determination of its identity is required before additional, more expensive testing is 
carried out. For a substance such as cocaine, the most common presumptive test 
being used is the Scott colour test. As can been seen in table 14, the sensitivity and 
specificity of this test are 0.68, 0.75 respectively (de Jong et al., 2018), giving an LR 
for a positive result of 2.72 (table 15). As shown in the earlier examples, if we wish to 
assess the posterior probabilities provided by a specific test, we need to assign 
relevant, reliable prior probabilities (which could be informed by studies on prevalence) 
in the circumstances being examined. In cases where there is a seizure of a 
substance, especially in powdered form, the priors could well be higher than 50% (50% 
reflecting maximum uncertainty).  Based on the circumstances of the seizure, on the 
packaging, its appearance and the place of storage of the powder or substance (for 
example, a sealed, clear package containing white powder in a toilet cistern), the 
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probability that the substance being seized was a controlled substance of a specific 
type would seem to be relatively high.  Reliable data to help assign priors in such 
circumstances do not appear to be available and therefore the expert needs to rely on 
their own knowledge and experience of drug seizures.  For this particular example, we 
have assigned an illustrative prior probability of 0.8 (80%).  The posterior probabilities 
resulting from positive test results can now be obtained by combining the prior 
probabilities with the LRs that were assigned from sensitivity and specificity data. 
Table 16 shows that, with a prior probability of 50% reflecting maximum uncertainty, 
the posterior probability is 73% when Test 1 is used. This posterior probability, as 
expected, increases to 92% when the prior probability is raised to 80% (because the 
prior information within the case circumstances caused the expert to assign a high 
probability of the seized substance being cocaine). The posterior probabilities of 
cocaine being present given a negative result, as shown in table 17, are not particularly 
low.  A posterior probability of 30% arises when the prior probability is 50% (maximum 
uncertainty); this posterior probability increases to 63% with a prior probability of 80%.  
A positive colour test provides a good probability that the substance is cocaine but, 
even with a negative result and a prior probability of 80%, there is a still a good 
probability that the substance is cocaine. Because of this risk of misleading inferences 
from negative results, the development of presumptive tests has concentrated on 
improving the sensitivity and specificity (and hence the magnitude of the LRs) of such 
tests.  For example, an electrochemical test for the detection of cocaine has improved 
the sensitivity and specificity of cocaine detection to 0.93 and 0.86 respectively (de 
Jong et al., 2018) (Table 14). This leads to an increased LR for positive detection (6.64 
for the electrochemical test compared to 2.72 for the colour test) and a decrease in 
the LR for a negative detection (0.08 for the electrochemical test compared to 0.43 for 
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the colour test). Tables 16 and 17 show that the electrochemical test has improved 
performance for both positive and negative results at prior probabilities of 50% and 
80%.   
If a decision was required on which of the two presumptive tests to use, the choice 
would seem to be a simple one, based on these data alone.  However, an additional 
consideration is the cost of the presumptive test and the cost of any confirmatory 
testing (see the earlier discussion of confirmatory testing and the requirement for proof 
“beyond a reasonable doubt”).  If we assume that both of the presumptive tests cost 
£1 and a confirmatory test costs £100, then we can determine the total costs of the 
testing regimes for 10,000 cases, assuming a prior probability of the substance being 
cocaine as 80%. In all cases, it was assumed confirmatory tests were only carried out 
if the preliminary test had given a positive result. Figure 3 and Table 18 shows that 
total costs of the colour test in this scenario are £604,000 and the electrochemical test 
£782,000. This difference in total costs is due to the electrochemical test detecting 
more positives correctly than the colour test. In this scenario, the use of a specific 
presumptive test (either the colour test or the electrochemical test) becomes more of 
a philosophical question that would need to be answered.  Is the increase in the 
predictive power of one presumptive test over another worth the increased long-term 
cost of using, in our example, the electrochemical test rather than the colour test?  If 
a suspect is equally likely to plead guilty given either presumptive test, then 
irrespective of that test’s effectiveness, the electrochemical test would, of course, be 
a better test to use. However, if all of the positive presumptive tests went to 
confirmatory tests, a decision would need to be made of cost versus benefit. Is the 
better test worth the increased costs that would be associated with it?  Of course, the 
cost of a test should not come into question as justice should not come with a price, 
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but often it does. For this reason, in many jurisdictions now, even with a guilty plea, 
the confirmatory test will always be completed. 
 
Conclusions 
When considering whether to carry out a particular presumptive test, it is important to 
take into account the prior probability of the substance being present.  That probability 
should be assigned according to what is known about the circumstances of the case 
and the person in question.  In the absence of anything specific about the case or 
person, one could default to a general prior for the group of which they are a member.  
In the complete absence of any information, then an uninformative prior probability of 
0.5, reflecting maximum uncertainty, could be adopted. This is not to say that a 
practitioner should just adopt a 0.5 prior because they are uncertain about an 
appropriate prior for the case in question.  It is very rare that there would be absolutely 
no knowledge or data to inform the prior. Every attempt should be made to gather data 
and information that would help assign a case-specific prior to avoid either a 
misleadingly high, or misleadingly low, resultant posterior probability. It is important for 
all forensic practitioners to understand the role that prior probability plays in drug 
screening and confirmation in order to interpret reliably and logically the results of 
toxicological testing.  
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Figure 1: Tree diagram of the false discovery rate of a cocaine screening test 
using fingermarks. This example assumes that 10,000 people living in Europe 
are randomly screened using the cocaine screening test. The prevalence of 
cocaine abuse in drivers is 0.42 %, the specificity of the test is 97.5 % and the 
sensitivity is 98.7 %. Out of the 10,000 people screened, 41+249 = 290 positive 
tests. 249 are false positives so the false discovery rate is 14%.  
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Figure 2: Graphical representation of the changes in the positive predictive 
value (PPV; the proportion of individuals with positive test results who are 
correctly identified as having consumed cocaine) and the negative predictive 
value (NPV; the proportion of individuals with positive test results who are 
incorrectly identified as having consumed cocaine). The sensitivity of the test 



































Figure 3: Tree diagram for a) the colour test (sensitivity 0.68 and specificity 0.75) and 
b) the electrochemical test (sensitivity 0.93 and 0.86) for cocaine. The example assume 
that 10,000 tests were carried out with 80% of the samples truly being cocaine.   Cost 




Total number of positive tests = 500+5440 = 5940 
Cost of Screening tests = 5940 * £100 = £594,000  
 
b)   
 
Total number of positive tests = 280+7440 = 7720 
Cost of Screening tests = 7720 * £100 = £772,000  
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Table 1. Rates of sensitivity and specificity  
Observation Drug present Drug not present  
Positive test result Sensitivity 1 - specificity  
Negative test result 1 - sensitivity Specificity  
    
 
Table 2.  Probability of the potential observations using test A, given the conditions of 
“Drug present’ and “Drug not present” and based on sensitivity and specificity data 
Observation Probability of 
observation,  
given drug present 
Probability of 
observation, given 
drug not present 
 
Positive test result 0.987 0.025  
Negative test result 0.013 0.975  
 1 1  
 
Table 3.  To show likelihood ratios (LRs) provided by the potential observations using 
test A 
Observation Probability of 
observation,  
given drug present 
Probability of 
observation, given 
drug not present 
Likelihood ratio 
Positive test result 0.987 0.025 39.48 
Negative test result 0.013 0.975 0.013 
 1 1  
 
Table 4.  Probability of the potential observations, and their respective likelihood 
ratios, for test B, based on metrics for sensitivity 99% and specificity of 99% 
respectively,  
Observation Probability of 
observation,  
given drug present 
Probability of 
observation, given 
drug not present 
Likelihood ratio 
Positive test result 0.99 0.01 99 
Negative test result 0.01 0.99 Approx. 0.01 
 1 1  
 
Table 5.  Probability of the potential observations, and their respective LRs, for test B, 
conditioned on a positive test observation with test A, 
Observation Probability of 
observation, given 
drug present and 
given +ve test A 
Probability of 
observation, given 
drug not present and 
given +ve test A 
Likelihood ratio 
Positive test result 0.999 0.1 Approx. 10 
Negative test result 0.001 0.9 Approx. 0.001 




Table 6: Effect of various values of prior probability on the posterior probability of the 
drug being present when using a presumptive test (test A: sensitivity 98.7%, specificity 
97.5% LR for a +ve result = 39.48) only and when combined with a confirmatory test 
(test B: conditional sensitivity 99.9%, conditional specificity 90%, conditional LR for a 
+ve result = 10).  
 
Prior probability (%) Posterior probability of drug 
being present given +ve Test A 
(%) 
Posterior probability of drug 
being present given +ve Test A  
and positive test B (%) 
0.1 4 29 
0.5 17 67 
1.0 28 80 
2.0 45 89 
5.0 68 96 




Table 7: The frequency of detection of a selection of drugs in alleged DFSA cases. 
Data taken from (Fiorentin & Logan, 2019) 
 











Table 8: Sensitivity and Specificity of various “drink spiking” presumptive tests for 
three DFSA drugs  
 




Drink Safe 1.2   
 GHB 0.5 0.916 
 Ketamine 0.5 0.916 




Drink Guard   
 GHB 0.5 0.766 
 Ketamine 0.25 0.766 




Drink Detective   
 Diazepam 0.813 0.879 
 GHB 0.175 0.879 
 Ketamine 1 0.879 




Table 9.  Probability of the potential observations, and their respective LRs, based on 
data in Table 8, for three drugs and three different tests 
 
Test/Drug Test observation Drug present Drug absent LR 
     
Drink Safe 1.2     
GHB     
 Positive 0.5 0.084 5.95 
 Negative 0.5 0.916 0.54 
  1 1  
     
Ketamine     
 Positive 0.5 0.084 5.95 
 Negative 0.5 0.916 0.54 
  1 1  
     
Drink Guard     
GHB     
 Positive 0.5 0.234 2.14 
 Negative 0.5 0.766 0.65 
  1 1  
     
Ketamine     
 Positive 0.25 0.234 approx. 1 
 Negative 0.75 0.766 approx. 1 
  1 1  
     
Drink Detective     
Diazepam     
 Positive 0.813 0.121 6.72 
 Negative 0.187 0.879 0.21 
  1 1  
     
GHB     
 Positive 0.175 0.121 1.44 
 Negative 0.825 0.879 approx. 1 
  1 1  
     
Ketamine     
 Positive 1 0.121 8.26 
 Negative 0 0.879 0 
  1 1  




Table 10.  Posterior odds and probabilities of the presence of the targeted drug, given 
a positive test observation and given prior probabilities based on prevalence shown 








      
Drink Safe 
1.2 
     
GHB 0.059 0.063 5.95 0.37 0.27 
      
Ketamine 0.005 0.005 5.95 0.03 0.03 
      
Drink Guard      
GHB 0.059 0.063 2.14 0.13 0.12 
      
Ketamine 0.005 0.005 ≈1 0.005 0.005 
      
Drink 
Detective 
     
Diazepam 0.037 0.038 6.72 0.26 0.205 
      
GHB 0.059 0.063 1.44 0.09 0.083 
      
Ketamine 0.005 0.005 8.26 0.042 0.040 




Table 11.  Posterior odds and probabilities of the presence of the targeted drug, given 









      
Drink Safe 
1.2 
     
GHB 0.5 1 5.95 5.95 0.86 
      
Ketamine 0.5 1 5.95 5.95 0.86 
      
Drink Guard      
GHB 0.5 1 2.14 2.14 0.68 
      
Ketamine 0.5 1 ≈1 1 0.50 
      
Drink 
Detective 
     
Diazepam 0.5 1 6.72 6.72 0.87 
      
GHB 0.5 1 1.44 1.44 0.59 
      
Ketamine 0.5 1 8.26 8.26 0.89 





Table 12.  Posterior odds and probabilities of the presence of the targeted drug, given 
a negative test observation and given prior probabilities based on prevalence shown 








      
Drink Safe 
1.2 
     
GHB 0.059 0.063 0.54 0.034 0.0327 
      
Ketamine 0.005 0.005 0.54 0.0027 0.0026 
      
Drink Guard      
GHB 0.059 0.063 0.65 0.0408 0.039 
      
Ketamine 0.005 0.005 ≈1 0.005 0.005 
      
Drink 
Detective 
     
Diazepam 0.037 0.038 0.21 0.0081 0.0075 
      
GHB 0.059 0.063 ≈1 0.063 0.059 
      
Ketamine 0.005 0.005 0 0 0 




Table 13.  Posterior odds and probabilities of the presence of the targeted drug, given 









      
Drink Safe 
1.2 
     
GHB 0.5 1 0.54 0.54 0.35 
      
Ketamine 0.5 1 0.54 0.54 0.35 
      
Drink Guard      
GHB 0.5 1 0.65 0.65 0.39 
      
Ketamine 0.5 1 ≈1 1 0.5 
      
Drink 
Detective 
     
Diazepam 0.5 1 0.21 0.21 0.17 
      
GHB 0.5 1 ≈1 1 0.5 
      
Ketamine 0.5 1 0 0 0 





Table 14: Sensitivity and specificity of 2 presumptive tests for cocaine, a colour test 







Sensitivity 0.68 0.93 
Specificity  0.75 0.86 
      
 
 
Table 15.  Probability of the potential observations, and their respective LRs, based 
on data in Table 14, for the two presumptive tests for cocaine. 
 
Test/Drug Test observation Drug present Drug absent LR 
     
     
     
Colour Test Positive 0.68 0.25 2.72 
 Negative 0.32 0.75 0.43 
  1 1  
     
     
Electrochemical 
Test 
Positive 0.93 0.14 6.64 
 Negative 0.07 0.86 0.08 





Table 16: Posterior odds and probabilities of the presence of the targeted drug 
(cocaine), given a positive test observation and given prior probabilities that reflect 1) 









colour 0.50 1 2.72 2.72 0.73      
0.80 4 2.72 10.88 0.92       
      
electro 0.50 1 6.64 6.64 0.87      
0.80 4 6.64 26.56 0.96 
 
 
Table 17: Posterior odds and probabilities of the presence of the targeted drug 
(cocaine), given a negative test observation and given prior probabilities that reflect 1) 







LR Posterior odds Posterior 
probability 
colour 0.50 1 0.43 0.43 0.30       
 
0.80 4 0.43 1.72 0.63       
      
electro 0.50 1 0.08 0.08 0.07       
 
0.80 4 0.08 0.32 0.24 
 
 
Table 18: Predicted total cost of each test (test 1 - colour test; test 2 – electrochemical 
test) based on 10,000 tests. Sensitivity and specificity are taken from table 14. The prior 



















Colour Test  1 £100 £10,000 £594,000 £604,000 
Electrochemical 
Test 1 £100 £10,000 £772,000 £782,000 
 
